Home » News » Drug Sponsors » InnFocus closes $33.9M Series C financing

InnFocus closes $33.9M Series C financing

Tuesday, December 22, 2015

InnFocus has closed its Series C financing, which raised additional monies to total $33.9 million.

The Miami-based company is developing the InnFocus MicroShunt (IMS) glaucoma drainage system to treat early, moderate and late-stage primary open angle glaucoma (POAG). The final phase of its FDA clinical trials will begin next month.

The InnFocus MicroShunt FDA clinical trial is the only company sponsored prospective randomized study that compares a device to the trabeculectomy procedure, which has been the “gold standard” for treating glaucoma for about 50 years. Patients with mild, moderate and severe glaucoma are included in the study.

Completion of phase I included more than 100 cases performed in the U.S. More than 250 patients have now been treated with the InnFocus MicroShunt device in Canada, France, Japan, the Netherlands, Spain, Switzerland, the Dominican Republic and the U.S.

The company has reported prospective results on mild, moderate, and severe glaucoma patients treated outside the U.S. with up to three years of follow up. Patients have experienced a mean reduction in intraocular pressure (IOP) from about 24 mm Hg on full medication to below 15 mm Hg, with more than 70% of patients completely off glaucoma medication three years after their surgery. Pressures below 15 mm Hg reduce a major risk factor for optic nerve damage and subsequent vision loss, which can occur when IOP is too high.

The InnFocus MicroShunt was developed in collaboration with the University of Miami’s Miller School of Medicine, Bascom Palmer Eye Institute. It provides a quick minimally invasive procedure for shunting aqueous humour from the anterior chamber to the same “gold standard” drainage path used in trabeculectomy. The device is made from SIBS, an innovative highly biocompatible material that has been implanted in the body for more than 15 years.

The InnFocus MicroShunt was designed to shunt aqueous humor without the need to cut scleral tissue, control suture tension, or utilize patch grafts. It has been implanted alone or in combination with cataract surgery in prospective studies outside the U.S.

Related Posts